8-K: Orthofix Reports Record Fourth Quarter and Full-Year 2024 Results, Provides 2025 Guidance

Orthofix Medical Inc. reported record fourth-quarter net sales and provided full-year 2025 financial guidance, focusing on profitable growth opportunities.

Summary

• Orthofix Medical Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided full-year 2025 financial guidance.
• Record fourth quarter net sales reached $215.7 million, an 8% increase year-over-year on both a reported and constant currency basis.
• U.S. Spine Fixation net sales grew by 12% compared to the fourth quarter of 2023.
• Record Bone Growth Therapies (BGT) net sales were $63.9 million, a 9% increase, with BGT Fracture net sales growing by 10%.
• Global Orthopedics net sales reached a record $35.8 million, representing constant currency growth of 18%.
• The company entered into a record number of 7D FLASH Navigation System placements for the full year 2024.
• The fourth quarter net loss was $(29.1) million, while non-GAAP adjusted EBITDA was $23.9 million, a $4.3 million increase.
• Free cash flow for the fourth quarter was $15.2 million, a significant improvement in cash usage.
• Full-year 2024 net sales were $799.5 million, a 7% increase on a reported and constant currency basis.
• Net loss for the full year was $(126.0) million, an improvement of 20% compared to the prior year.
• Non-GAAP adjusted EBITDA for the full year was $67.4 million, a 46% increase compared to 2023.
• The company is discontinuing its M6-C artificial cervical disc and M6-L artificial lumbar disc product lines.
• Global net sales for the M6-C and M6-L discs were $23.4 million in 2024.
• Net sales for 2025 are expected to range between $818 million and $826 million, excluding M6 sales.
• Non-GAAP adjusted EBITDA for 2025 is expected to be $82 million to $86 million.
• The company expects positive free cash flow for full-year 2025, excluding restructuring charges related to the M6 discontinuation.
• The long-term net sales CAGR target has been increased to 6.5% to 7.5% from the previous 6% to 7%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record sales, increased growth targets, and a focus on profitable growth opportunities. While there are some negative aspects, such as net losses and the discontinuation of a product line, the overall tone is optimistic and forward-looking.

Positives

• Record fourth-quarter net sales of $215.7 million, an 8% increase year-over-year.
• U.S. Spine Fixation net sales grew by 12% compared to the fourth quarter of 2023.
• Bone Growth Therapies (BGT) net sales reached a record $63.9 million, a 9% increase.
• Global Orthopedics net sales reached a record $35.8 million, representing constant currency growth of 18%.
• Non-GAAP adjusted EBITDA for the fourth quarter was $23.9 million, a 22% increase year-over-year.
• Free cash flow for the fourth quarter was $15.2 million, a significant improvement.
• Full-year 2024 net sales were $799.5 million, a 7% increase year-over-year.
• Non-GAAP adjusted EBITDA for the full year was $67.4 million, a 46% increase year-over-year.
• The company expects positive free cash flow for 2025.
• The long-term net sales CAGR target has been increased to 6.5% to 7.5%.

Negatives

• Fourth quarter 2024 net loss of $(29.1) million, or $(0.75) per share.
• Full-year 2024 net loss of $(126.0) million, or $(3.30) per share.
• Discontinuation of the M6-C and M6-L artificial disc product lines, resulting in restructuring charges.
• Gross margins were 69.0% for the quarter and were 68.3% for the year.
• The company expects a negative impact from foreign currency of approximately $4 million, or 50 basis points, on a reported basis, as compared to the full-year 2024.

Risks

• The company's ability to maintain operations to support customers and capitalize on future growth opportunities.
• Risks associated with the acceptance of surgical products and procedures by surgeons and hospitals.
• Development and acceptance of new products or product enhancements.
• The company's ability to adequately manage inventory.
• The company's success in defending legal proceedings brought against it.
• The company is unable to predict, without unreasonable efforts, the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating adjusted EBITDA.

Future Outlook

The company expects net sales between $818 million and $826 million for 2025, excluding M6 sales, and non-GAAP adjusted EBITDA between $82 million and $86 million, with positive free cash flow. The long-term net sales CAGR target has been increased to 6.5% to 7.5%.

Management Comments

• We are pleased with the performance of the Orthofix team to serve our surgeons and patients and successfully execute our plans throughout 2024, said Massimo Calafiore, President and CEO.
• Our fourth quarter results reflect outstanding performance across all three major product lines, providing further evidence that Orthofixs balanced and complementary product mix offers a differentiated advantage across multiple markets.
• We enter 2025 with great momentum as two integrated organizations.
• The entire team remains focused on executing our priorities, and I look forward to leveraging our unique portfolio platform to drive value creation through profitable growth in 2025 and beyond.

Industry Context

Orthofix operates in the global medical technology industry, focusing on musculoskeletal pathologies. The company's performance is influenced by factors such as the acceptance of surgical products, the development of new products, and evolving standards of care. The company competes with other medical device companies in the spine, orthopedics, and bone growth therapies markets.

Comparison to Industry Standards

• The company's U.S. Spine Fixation growth of 12% significantly outpaces the market rate.
• The company's focus on innovation, particularly with the 7D FLASH Navigation System, positions it well in the enabling technologies market.
• The company's discontinuation of the M6 artificial disc product lines reflects a strategic shift towards more profitable growth opportunities, similar to actions taken by other companies in the medical device industry to optimize their portfolios.

Stakeholder Impact

• Shareholders: The company's increased growth targets and focus on profitability are likely to be viewed positively by shareholders.
• Employees: The company's success and focus on growth may create opportunities for employees.
• Customers: The company's continued innovation and focus on providing life-changing solutions are likely to benefit customers.
• Suppliers: The company's growth may lead to increased demand for suppliers.
• Creditors: The company's improved financial strength and positive free cash flow outlook are likely to be viewed favorably by creditors.

Next Steps

• The company will provide a full update on the accounting treatment and financial impact for the discontinuation of the M6 product lines on its first quarter 2025 earnings call.
• The company expects to use the corporate investor relations presentation in connection with presentations to investors, analysts, and others during the fiscal year ending December 31, 2025.

Key Dates

Keywords

Orthofix, Net Sales, EBITDA, Bone Growth Therapies, Spine Fixation, Orthopedics, Financial Results, Guidance